QCM
DNLI icon

Quantinno Capital Management’s Denali Therapeutics DNLI Stock Holding History

Quantinno Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$968K Buy
37,651
+7,481
+25% +$154K ﹤0.01% 2586
2026
Q1 		$579K Buy
30,170
+3,857
+15% +$76.7K ﹤0.01% 2604
2025
Q4 		$434K Buy
26,313
+1,606
+7% +$27.1K ﹤0.01% 2555
2025
Q3 		$359K Buy
+24,707
New +$355K ﹤0.01% 2302

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quantinno Capital Management's DNLI Position: Q2 2026 in Review

Quantinno Capital Management increased its Denali Therapeutics (DNLI) stake by 25% in Q2 2026, buying an estimated $154K and bringing the position to 37,651 shares worth $968K. The position accounts for ﹤0.01% of the portfolio, ranked #2586.

Quantinno Capital Management first reported a position in DNLI in Q3 2025 and has held it in 4 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Quantinno Capital Management held 37,651 shares of Denali Therapeutics worth $968K as of Q2 2026.
  • Quantinno Capital Management bought 7,481 Denali Therapeutics shares in Q2 2026, an estimated $154K.
  • Denali Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2586 holding.
  • Quantinno Capital Management first reported a position in Denali Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.